Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

R. G. Langley*, K. Papp, A. B. Gottlieb, G. G. Krueger, K. B. Gordon, D. Williams, J. Valdes, C. Setze, B. Strober

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Fingerprint Dive into the research topics of 'Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis'. Together they form a unique fingerprint.

Medicine & Life Sciences